Breast Cancer. Malignant neoplasm of breast
Conditions
Interventions
Intervention 1: Intervention group: Escitalopram (Escitalopram) of Abidi Pharmaceutical Company at the rate of 10 mg daily along with therapeutic intervention based on mindfulness for 8 weeks (1 sessi
Sponsors
Babol University of Medical Sciences
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Patients in the 2 and 3 stages of breast cancer Ability to answer the questionnaire and reading and writing literacy Obtaining the minimum anxiety and depression score based on the Hospital Anxiety and Depression Scale (HADS)
Exclusion criteria
Exclusion criteria: Failure to attend more than two sessions out of a total of 8 intervention sessions Using psychoactive drugs to reduce the symptoms of anxiety and depression Disease recurrence or metastasis in other parts of the body during research Cognitive disorders and delirium and dementia Taking other psychiatric drugs or substance dependence
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Psychological problems (depression, anxiety). Timepoint: Before starting the intervention, after 4 weeks and finally 8 weeks. Method of measurement: Hospital Anxiety and Depression Standard Questionnaire (HADS).;Sleep Quality. Timepoint: Hospital Anxiety and Depression Standard Questionnaire (HADS). Method of measurement: Petersburg Sleep Questionnaire (PSQI). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarzan Kheirkhah
Babol University of Medical Sciences
Outcome results
None listed